TransMedics outlines 20-25% 2026 revenue growth target while advancing OCS programs and European expansion
Source: SeekingAlpha
2026-02-25 02:08:36 ET
More on TransMedics Group
- TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
- TransMedics: Italian NOP Program Reinforces Huge International Opportunity
- TransMedics: Strong Growth And A Better Setup
- TransMedics Group GAAP EPS of $2.62 beats by $2.26, revenue of $160.8M beats by $5.52M
- Seeking Alpha’s Quant Rating on TransMedics Group
Read the full article on Seeking Alpha
For further details see:
TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
TransMedics Group Inc.
NASDAQ: TMDX
TMDX Trading
0.6% G/L:
$130.85 Last:
200,873 Volume:
$133.51 Open:
TMDX Latest News
March 08, 2026 05:42:00 am
TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
February 28, 2026 12:50:00 pm
Got $5,000? TransMedics Could Be a High?Tech Organ Transplant Moonshot
TMDX Stock Data
$4,701,020,147
32,055,517
1.45%
174
N/A
Medical Equipment & Supplies
Healthcare
US
Andover
